Geneva Capital Management LLC raised its holdings in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 14.3% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 149,856 shares of the medical device company’s stock after acquiring an additional 18,773 shares during the quarter. Geneva Capital Management LLC’s holdings in DexCom were worth $12,931,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also bought and sold shares of DXCM. Legal & General Group Plc bought a new stake in shares of DexCom during the second quarter worth $173,237,000. Deutsche Bank AG bought a new position in shares of DexCom in the second quarter worth about $164,035,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of DexCom by 15.6% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock worth $758,487,000 after purchasing an additional 1,515,702 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of DexCom in the second quarter worth about $89,940,000. Finally, Arrowstreet Capital Limited Partnership increased its stake in DexCom by 100.4% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,545,103 shares of the medical device company’s stock worth $159,832,000 after buying an additional 1,275,142 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the stock. Royal Bank Of Canada reiterated an “outperform” rating and set a $105.00 price objective (up from $90.00) on shares of DexCom in a report on Thursday, October 1st. JPMorgan Chase & Co. upped their target price on shares of DexCom from $82.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, October 30th. Weiss Ratings upgraded shares of DexCom from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, October 6th. Canaccord Genuity Group raised their target price on shares of DexCom from $90.00 to $97.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Finally, Leerink Partners reduced their target price on shares of DexCom from $94.00 to $87.00 and set an “outperform” rating on the stock in a research report on Monday, October 26th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, DexCom has an average rating of “Buy” and an average price target of $95.50.
Check Out Our Latest Research Report on DXCM
Insider Buying and Selling at DexCom
In other news, EVP Jereme Sylvain sold 3,638 shares of the business’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $83.27, for a total value of $302,936.26. Following the completion of the sale, the executive vice president owned 146,828 shares in the company, valued at approximately $12,226,367.56. The trade was a 2.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Brown sold 1,700 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $85.48, for a total transaction of $145,316.00. Following the completion of the sale, the executive vice president directly owned 98,185 shares of the company’s stock, valued at $8,392,853.80. The trade was a 1.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 22,822 shares of company stock valued at $1,920,193 in the last 90 days. Insiders own 0.28% of the company’s stock.
DexCom Price Performance
DXCM opened at $83.33 on Monday. DexCom, Inc. has a 12-month low of $56.72 and a 12-month high of $92.59. The company has a current ratio of 1.74, a quick ratio of 1.40 and a debt-to-equity ratio of 0.49. The business’s fifty day simple moving average is $84.30 and its 200-day simple moving average is $75.21. The company has a market capitalization of $31.08 billion, a price-to-earnings ratio of 32.68, a PEG ratio of 1.38 and a beta of 1.45.
DexCom (NASDAQ:DXCM – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.68 by $0.05. The firm had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. DexCom had a return on equity of 37.77% and a net margin of 19.42%. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.61 earnings per share. On average, equities research analysts anticipate that DexCom, Inc. will post 2.68 earnings per share for the current fiscal year.
About DexCom
DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.
Featured Articles
- Five stocks we like better than DexCom
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
